Hematologic Oncology

Recent research found that the disialoganglioside 2–directed bispecific trifunctional antibody has 2 binding sites which allows for a mitigated T-cell anti-tumor response.

Alex Kradhim reviews how graft-versus-host disease can be maintained by tissue resident TCF-1+ T cells.

Alison Gulbis, PharmD, BCOP, discusses her experience of being a woman in the bone marrow transplant and cellular therapy field.

The addition of bortezomib to dexamethasone plus rituximab and cyclophosphamide appears to improve progression-free survival among those with Waldenström Macroglobulinemia.

Findings from a German register-based study suggests that more attention should be paid to sexual health among long-term hematological cancer survivors.

Co-editor-in-Chief Julie M. Vose, MD, MBA, reviews the most prominent developments from the 64th Annual Meeting of the American Society of Hematology.

Expert hematologist-oncologists review the clinical data on the long-term use of tagraxofusp and share their real-world experiences.

An expert from the Georgia Cancer Center underscores the need to proactively address socioeconomic challenges in survivors of hematologic cancer.

Findings from a randomized trial indicate that therapeutic education plus physical activity are safe, feasible, and potentially effective for patients with hematologic cancer.

Eleanor Mayfield, ELS, reviews the role of bispecific antibodies in hematologic malignancies.

Data from the phase 2 PIONEER trial supports the supplemental new drug application for avapritinib in adult patients with indolent systemic mastocytosis, an uncontrolled proliferation and activation of mast cells.

An expert from Augusta University says cancer care should extend beyond treatment and highlights why unmet social needs should be a consideration for survivors of hematologic cancer, especially those with a lower socioeconomic status or who are of a racial or ethnic minority.

Patients who are set to undergo autologous hematopoietic stem cell transplant following induction chemotherapy may have poor mobility across several domains vs an age-matched control group.

After sharing key takeaways on the management of BPDCN, expert hematologist-oncologists highlight unmet needs and forecast evolutions in care.

Before closing out their review of adverse events associated with tagraxofusp, Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on the identification and management of myelosuppression.

A brief review of the role of tagraxofusp as bridging therapy to stem cell transplant in patients diagnosed with blastic plasmacytoid dendritic cell neoplasm.

Comprehensive discussion on the management of adverse events associated with tagraxofusp and how BPDCN care can be optimized in the setting of academic centers.

Alex Kadhim investigates outcomes in infant patients who receive blood and marrow transplantation.

Centering discussion on a recent study, experts Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on long-term data with tagraxofusp in BPDCN.

Expert hematologist-oncologists share their perspective on the broad diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Patients with B-cell malignancies intolerant to acalabrutinib appeared to derive clinically meaningful benefit from zanubrutinib.

A 3-drug regimen with post-transplant cyclophosphamide may represent a new prophylactic option for well-matched adults with graft-versus-host disease who underwent reduced-intensity transplant.

Among patients with paroxysmal nocturnal hemoglobinuria, crovalimab yielded stable rates of hemolysis control and transfusion avoidance in the phase 3 COMMODORE trial.

The BTK inhibitor pirtobrutinib demonstrated high response rates in pretreated patients with Waldenström macroglobulinemia, according to recent data.

Revumenib, which was given a breakthrough therapy designation by the FDA, may be beneficial in the management of relapsed or refractory KMT2A-rearranged acute leukemia based on data from the phase 1 AUGMENT-101 trial.